Navigation Links
Pharmaceutical Direct to Consumer Advertising on The American Law Journal
Date:1/17/2010

PHILADELPHIA, Jan. 17 /PRNewswire/ -- In the last decade, the number of consumers taking antidepressants has more than doubled, with a staggering 4000% increase in the diagnosis of bipolar disorder in children in that time.  Doctors wrote 164 million prescriptions for antidepressants in 2008. Pharmaceutical companies spend billions of dollars on direct to consumer pharmaceutical advertising psychiatric drugs. Is there a connection? And when a patient experiences harm from a drug, does direct to consumer advertising play a role in litigation?

Monday January 18 live from 7:00-8:00 p.m. EST on the Philadelphia CNN-News affiliate WFMZ-TV and streaming online at WFMZ.com, The American Law Journal presents "Ask Your Doctor If 'x' is Right for You— Does Drug Advertising Help or Hurt the Consumer?" Philadelphia-based lawyers and a prominent pain physician address the legal, medical and social implications of direct to consumer drug advertising. Former New Jersey prosecutor Christopher Naughton, a legal commentator and 20-year legal broadcasting veteran, hosts the program.

On the panel representing consumers and pharmaceutical whistleblowers in nationwide, complex pharmaceutical litigation and recent landmark pharmaceutical settlements is Stephen Sheller, Esq. of the law firm of Sheller, P.C.. Raymond Williams, Esq. of DLA Piper brings his expertise defending top-tier pharmaceutical companies in high-profile cases to the conversation. Joining Sheller and Williams is physician Frank J.E. Falco, M.D., CEO of the Mid-Atlantic Spine & Pain Physicians and Vice President of the American Society of Interventional Pain Physicians. The program will address both informational and product drug advertising with an emphasis on the rapid growth of marketing and prescribing antidepressant and antipsychotic drugs.

Despite health concerns and the increase in lawsuits involving antipsychotic drugs, "we're seeing more drug advertising with 'if you're antidepressant isn't doing enough for you' ads," says Sheller, "and with the FDA approving the use of antipsychotics in children, it's becoming a huge moral question."

The American Law Journal is a weekly talk-feature program that addresses consumer, business and constitutional law. The program is seen throughout the Philadelphia tri-state region, streams live, and is available for download. Free links for downloads are available by request from info@lawjournaltv.com while the program website is under renovation. Next week on The American Law Journal: "The Lawyer, the Client, the Insurance Adjuster & the Judge."

Available Topic Experts: For information on the listed expert(s), click appropriate link.

Christopher Naughton   |   https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=85988

Stephen  Sheller, Esq.   |   https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=85992

SOURCE The American Law Journal


'/>"/>
SOURCE The American Law Journal
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud ... and unique items from across the nation, this holiday-themed event will raise funds and ... the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
Breaking Medicine News(10 mins):